

Development and validation of an *in vitro* HTS assay that mimics urine conditions to identify new compounds active against multidrug-resistant uropathogenic enterobacteria



Mercedes de la Cruz*, Pilar Sánchez, José Rubén Tormo, Germán Martínez, Jesús Martín, Francisca Vicente and Olga Genilloud


Fundación MEDINA, Parque Tecnológico de Ciencias de la Salud, Avda. del Conocimiento 34, 18016 Granada, SPAIN

*mercedes.delacruz@medinaandalucia.es

www.medinadiscovery.com


INTRODUCTION

- The increase in **antibiotic resistance** is limiting the therapeutic options for bacterial infections, especially those involving the most prevalent **Gram-negative pathogens**.
- The **expression pattern of essential genes** is not only strain-dependent but is also **influenced by the environment** of infection, which conditions typically **do not correlate with the conditions used in *in vitro* assays**.
- We hypothesize that a differential assay that mimics the infection microenvironment may lead to the discovery of new antibiotics.
- This project uses **urinary tract infection** in combination with **natural products** of microbial origin to identify **new potential antibiotics**.




MATERIAL AND METHODS

1.- Uropathogenic *Escherichia coli* strains (UPEC) for *in vitro* HTS assays



(Maria E. Terlizzi, Giorgio Gribaudo and Massimo E. Maffei, Front. Microbiol., 2017)


3.- Fundación MEDINA's Natural Products Libraries



2.- Liquid Culture media for *in vitro* HTS assays

- MHII:** (Muller Hinton II) non-selective growth medium commonly used in research laboratories.
- AUM:** Artificial Urine Medium (Brooks *et al.* 1997) that mimics the physiological environment of urinary pathogens.

4.- Measurement of bacterial growth by luminescence (BacTiter-Glo™)



5.- Dereplication of known compounds by LCMS-HR (High Resolution Liquid Chromatography Mass Spectrometry)


RESULTS

1.- Set Up and Validation of *in vitro* HTS assay (BacTiter-Glo™)

1.1- Absorbance as a measure of bacterial growth is discarded

AUM medium creates **crystals** that precipitate and obstruct the correct reading of optical density (OD).

Low growth of both **UPEC pathogens** in AUM medium that hinders a good assay window (S/B).




UPEC strains **Growth Curves** measured with luminescence in **MHII** and **AUM** culture media using BacTiter-Glo™.

1.2- Optimal HTS assay Conditions

Conc. inoculum: 5×10^5 CFU/mL
 V_{inoculum} : 25 μ L V_{extracts} : 2.5 μ L
 $V_{\text{assay final}}$: 27.5 μ L $V_{\text{BacTiter Glo}}$: 25 μ L
 Incubation Time: T_{AUM} 7h; T_{MHII} 6h

Higher accuracy and sensitivity
 Improved QC parameters: RZ' , CV and S/B
 Better minimized assay costs and times



1.3- Antibiotic Minimal Inhibiting Concentration MIC (μ g/mL) Validation


MIC (μ g/mL) values against both UPEC strains grown in **MHII** and **AUM** for 6 and 7 hours.

ANTIBIOTIC	UPEC536 AUM (7hr)	UPEC536 MHII (6hr)
Ác.Nalidixic	≤ 128	≤ 64
Ceftazidime	≤ 128	16
Levofloxacin	0.25	0.5
Meropenem	4	1
Nitrofurantoin	64	4

ANTIBIOTIC	CFT073 AUM (7hr)	CFT073 MHII (6hr)
Ác.Nalidixic	>128	64
Ceftazidime	128	32
Levofloxacin	4	0.5
Meropenem	16	4
Nitrofurantoin	128	64


2.- Data Analysis from Pre-Screening HTS assay

2.1- Screening of 1520 extracts tested in duplicate against both UPEC strains in both MHII and AUM



Activity distribution and correlation of extracts tested against **both UPEC strains** grown in **MHII** and **AUM** (bold numbers are active extracts that showed inhibition >70%).


2.2- Distribution of 64 active extracts



Activity Cut off: inhibition > 70% and SD < 30%.

2.2- LCMS-HR analysis of 64 active extracts

a) 43 out of 64 extracts contain **known compounds** such as oxytetracycline, illudin, virginiamycin, nocardamine and griseofulvin, among others.



b) 21 out of 64 extracts showed **no coincidences** with known molecules registered in MEDINA's database or in the Dictionary of Natural Products.

CONCLUSIONS

- UPEC_536 is more sensitive than ATCC700928 (CFT073) in both HTS assay conditions (**MH II** and **AUM**).
- The 21 extracts with no match in the chromatographic profile have been selected for further studies to **purify and elucidate the structure** of the active compounds.
- Our next goal is to determine the mode of action of the specific extracts that are active in the urine-mimicking growth conditions (**AUM**).

FUNDING: Proyecto ISCIII_PI19/00921: Nuevos antibióticos contra patógenos Gram negativos multiresistentes (2020-2022)

